influencing postoperative clinical parameters in patients with transurethral prostatic surgery.
INTRODUCTION AND OBJECTIVES:
There is accumulating evidence that variations in the human microbiota may promote different benign disease conditions. Our goal was to examine the association between urinary and fecal microbial profiles and the different aspect of lower urinary tract symptoms (LUTS) in adult males.
METHODS: We extracted total DNA from urine and fecal samples and collected international prostate symptom score (I-PSS) data from a group of adult males through an intuitional review board approved protocol. We then amplified the extracted DNA and sequenced it using bacterial 16S rRNA gene high-throughput next-generation sequencing platform, and analyzed microbial profiles for taxonomy to examine the association between the different operational taxonomy units (OTUs) and LUTS represented by the overall all I-PSS score and its subcomponents of storage, nocturia, voiding, and bother. RESULTS: We included 30 patients in our analysis (60 samples, one urine and one fecal per patient). Characteristics of the study subject 0 s LUTS are illustrated in table 1. Forty-eight fecal OTUs showed significant association with one or more of the I-PSS components; 27 with nocturia, 19 with bother, 16 with storage symptoms, and 9 with voiding complaints. The strongest association was between Lachnospiraceae Blautia, a bacteria that increases the availability of gut anxiolytic and antidepressant short chain fatty acids, and bother (correlation coefficient -0.702). Ten urinary OTUs showed significant association with LUTS; 8 with nocturia, 1 with bother, 3 with storage, and 1 with void. The abundance of one urinary bacteria that belongs to a family previously shown to be enriched in patients with bladder cancer, Ruminococcaceae Gemmiger, was common to increased voiding, storage, and nocturia scores CONCLUSIONS: Our prospective work finds plausible correlation between urinary and fecal microbiota and LUTS. However, due to the limited number of participants additional studies are needed to determine if the associations found in this research are applicable to the general population of patients affected by LUTS. 
Leptin is a metabolic peptide hormone produced by adipocytes, with assumed roles in proflieration of prostate cancer cells and of prostate cells in animal models of benign prostatic hyperplasia (BPH). Thus, a role of leptin as a molecular link connecting BPH and lower urinary tract symptoms (LUTS) suggestive of BPH with metabolic syndrom appears possible/feasible, but is still unknown. In fact, a connection between metabolic syndrome and BPH/LUTS is becoming increasingly evident from epidemiologic studies. Key factors of LUTS suggestive of BPH are an increased prostate smooth muscle tone, and prostate enlargement, which may both contribute to bladder outlet obstruction. Here, we examined the effects of leptin on contraction of human prostate smooth muscle and on growth of stromal cells.
METHODS: Human prostate tissues were obtained from patients undergoing radical prostatectomy. Contractions of prostate strips were studied in an organ bath, using tissues from n[5 patients for each control and leptin group. Proliferation and viability of human prostate stromal cells (WPMY-1) were assessed by EdU and CCK-8 assays (five independent experiments for each). Mitochondrial-related apoptosis was examined by near-infrared (NIR) fluorescent dye and analysis by flow cytometry (FACS).
RESULTS: Electric field stimulation induced frequency-dependent, neurogenic contractions of human prostate tissues. These contractions were enhanced concentration-dependently by leptin (50 nM, 100 nM), which was significant using 100 nM of leptin (p<0.05 at 16 Hz for leptin vs. control, with 47AE7% of KCl-induced contraction in control, and 99.8AE22% in leptin group). As shown by CCK-8 assay, leptin increased the viability of WPMY-1 cells, which was observed at different concentrations (6.25-50 ng/ml), and with similar levels of viability at all concentrations. Leptin-induced proliferation (24 h) was confirmed by EdU assay (p[0.024 at 25 ng/ml leptin, with 54 AE8.8% of cells under proliferation in control group, and 68 AE5.9% in leptin-stimulated cells). Leptin (25 ng/ml) increased NIR stain intensity in FACS analysis (p[0.035), reflecting attenuated apoptosis in WPMY-1 cells.
CONCLUSIONS: Leptin promotes smooth muscle contraction and growth of stromal cells in the human prostate, suggesting that leptin might be an important factor aggravating LUTS/BPH in obese male patients. Patients suffering from metabolic syndrom plus LUTS/BPH may profit from leptin management. The leptin system in LUTS/BPH merits further consideration.
